Global News

Keryx initiates phase II study of Zerenex in chronic kidney disease

Thursday, November 1, 2012 10:25 AM

Keryx Biopharmaceuticals, a biopharmaceutical company based in New York, N.Y., has initiated a phase II study of Zerenex (ferric citrate), the company's ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).

More... »

$11.3M awarded to researchers through MRC-AZ compound collaboration

Thursday, November 1, 2012 09:56 AM

The Medical Research Council (MRC) has awarded $11.3 million of funding for 15 research projects awarded through its collaboration with global biopharmaceutical company AstraZeneca, which gave academic researchers unprecedented access to 22 chemical compounds.

More... »

Charles River to acquire Vital River, expands research models business

Thursday, November 1, 2012 09:28 AM

Charles River Laboratories International, a global provider of research products and services, has entered into an agreement to acquire 75% ownership of Vital River, a Chinese commercial provider of research models and related services.

More... »

The CenterWatch Monthly, November 2012

Thursday, November 1, 2012 08:00 AM

Keeping potential patients connected to trials

More... »

Thesan Pharmaceuticals closes $16M Series A funding

Wednesday, October 31, 2012 02:04 PM

Thesan Pharmaceuticals, a newly-formed biotech focused on dermatological conditions, has closed a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds. 

More... »

Theratechnologies revises business plan, cuts 15 employees

Wednesday, October 31, 2012 10:39 AM

Theratechnologies, a Canadian specialty pharmaceutical company focused on therapeutic peptide products, has revised its business plan which will focus on revenue growth from tesamorelin in the short term and expenditure control.

More... »

Apredica, Pfizer ink collaborative research agreement

Wednesday, October 31, 2012 09:43 AM

Apredica, a subsidiary of Cyprotex, a preclinical ADME-Tox services company, has signed a collaborative research agreement with Pfizer, a global research-based pharmaceutical company.

More... »

Bayer to acquire Schiff Nutrition International for $ 1.2B

Wednesday, October 31, 2012 09:15 AM

Bayer HealthCare has signed a merger agreement to acquire Schiff Nutrition International, a company offering vitamins and nutritional supplements in the U.S. and other countries, for $1.2 billion, representing a value of $34 per share in cash.

More... »

Evotec, CHDI Foundation extend collaboration in Huntington's

Tuesday, October 30, 2012 12:23 PM

CHDI Foundation, a privately-funded not-for-profit research organization dedicated to developing therapies for Huntington's disease, has extended its collaboration with Evotec, a drug discovery alliance and development partnership company based in Germany, until the end of 2015. The contract extension could be worth up to $41 million in research payments for Evotec.

More... »

Shionogi, ViiV Healthcare to commercialize and develop integrase inhibitor portfolio

Tuesday, October 30, 2012 11:19 AM

ViiV Healthcare, a global specialist HIV company based in the U.K., and Shionogi, a Japanese research-driven pharmaceutical company, have entered into an agreement substantially revising their integrase inhibitor relationship.

More... »